Exelixis | EXEL - Ebitda



Exelixis reported $220.92M in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
Agios Pharmaceuticals USD -125797000 20.45M Jun/2025
Amgen USD 3.6B 147M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
Bayer EUR 236M 3.35B Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Cytokinetics USD -153331000 16.67M Mar/2025
Eisai JPY 8.81B 28.8B Mar/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Exelixis USD 220.92M 26.71M Jun/2025
Genmab DKK 376M 172M Jun/2025
Glaxosmithkline GBP 3.23B 1.54B Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD 150.23M 291.7M Jun/2025
MacroGenics USD -33437000 17.35M Jun/2025
Merck USD 7.74B 625M Mar/2025
Moderna USD -760000000 164M Jun/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
Novartis USD 6.17B 339M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
Sanofi EUR 1.89B 1.33B Jun/2025
Takeda JPY 366.2B 238.06B Jun/2025
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
Xencor USD -30519000 6.39M Jun/2025